lindner: Lindner Center for Research and Education study on Abciximab...

Description Format References

Description

The effects of Abciximab use on both survival and cardiac billing.

Format

A data frame with 996 rows and 10 columns:

lifepres

Life years preserved post treatment: 0 (died) vs. 11.6 (survived).

cardbill

Cardiac related billing in dollars within 12 months.

abcix

Indicates whether the patient received Abciximab treatment: 1=yes 0=no.

stent

Was a stent depolyed? 1=yes, 0=no.

height

Patient height in centimeters.

female

Patient sex: 1=female, 0=male.

diabetic

Was the patient diabetic? 1=yes, 0=no.

acutemi

Had the patient suffered an acute myocardial infarction witih the last seven days? 1=yes, 0=no.

ejecfrac

Left ventricular ejection fraction.

ves1proc

Number of vessels involved in the first PCI procedure.

References

Kereiakes DJ, Obenchain RL, Barber BL, Smith A, McDonald M, Broderick TM, Runyon JP, Shimshak TM, Schneider JF, Hattemer CR, Roth EM, Whang DD, Cocks D, Abbottsmith CW. Abciximab provides cost-effective survival advantage in high-volume interventional practice. Am Heart J. 2000;140(4):603-610.


LocalControl documentation built on May 2, 2019, 7:29 a.m.